Completed PHASE3 INTERVENTIONAL 2-arm NCT04797013

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ (TRACEⅡ)

A Phase 3, Multicentre,Open-label, Randomised Controlled, Non-inferiority Trial

Sponsor: Beijing Tiantan Hospital

Updated 6 times since 2021 Last updated: Jan 13, 2023 Started: Jun 12, 2021 Primary completion: May 29, 2022 Completion: Jul 15, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Ischemic Stroke, this trial is completed. The trial is conducted by Beijing Tiantan Hospital and has accumulated 6 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Oct 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2023 — Jul 2024 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Sep 2021 — Feb 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Apr 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tiantan Hospital
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Data source: Beijing Tiantan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baotou, China , Beijing, China , Changchun, China , Changzhi, China , Chengde, China , Chifeng, China , Chongqing, China , Daqing, China , Datong, China , Guangdong, China and 36 more locations